Consequences of low levels of nicotinic acetylcholine receptors in schizophrenia for drug development

Drug Development Research

Volumn 60, Issue 2, 2003, Pages 127-136

  Leonard, Sherry ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Addiction; Drug development; Nicotine; Nicotinic receptor; Schizophrenia; Smoking

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ALPHA BUNGAROTOXIN; AMFEBUTAMONE; CLOZAPINE; GALANTAMINE; IODINE 125; MECAMYLAMINE; NEUROLEPTIC AGENT; NICOTINIC AGENT; NICOTINIC RECEPTOR; OLANZAPINE;

ALCOHOL CONSUMPTION; BINDING AFFINITY; BRAIN REGION; CHOLINERGIC SYSTEM; COGNITION; DEPTH PERCEPTION; DIABETES MELLITUS; DRUG DESIGN; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE MUTATION; GENETIC LINKAGE; HUMAN; INCIDENCE; INHIBITION KINETICS; NEUROTRANSMISSION; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SACCADIC EYE MOVEMENT; SCHIZOPHRENIA; SELF MEDICATION; SMOKING CESSATION; SMOKING HABIT; WORKING MEMORY;

EID: 0141928543     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10292     Document Type: Review

References (103)

1. Abel LA, Friedman L, Jesberger J, Malki A, Meltzer HY. 1991. Quantitative assessment of smooth pursuit gain and catch-up saccades in schizophrenia and affective disorders. Biol Psych 29:1063-1072.
2. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R. 1992. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psych 32:607-616.
3. Adler LE, Hoffer LD, Wiser A, Freedman R. 1993. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psych 150:1856-1861.
4. Adler LE, Olincy A, Waldo MC, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R. 1998. Schizophrenia, sensory gating, and nicotinic receptors. Schiz Bull 24:189-202.
5. Alkondon M, Albuquerque EX. 2001. Nicotinic acetylcholine receptor alpha 7 and alpha 4 beta 2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol 86:3043-3055.
6. Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX. 1997. Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci 9: 2734-2742.
7. Allen TB, McEvoy JP. 2002. Galantamine for treatment-resistant schizophrenia. Am J Psych 159:1244-1245.
8. Anand R, Peng X, Lindstrom J. 1993. Homomeric and native 7 acetylcholine receptors exhibit remarkably similar but non-identical pharmacological properties, suggesting that the native receptor is a heteromeric protein complex. FEBS 327:241-246.
9. 3H]Nicotine binding in peripheral blood cells of smokers is correlated with the number of cigarettes smoked per day. Neuropharmacology 39:2818-2829.
10. Benowitz NL. 1992. Cigarette-smoking and nicotine addiction. Med Clin N Am 76:415-437.
11. 3H] nicotine binding sites in human brain. J Neurochem 50:1243-1247.
12. Berger F, Gage FH, Vijayaraghavan S. 1998. Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells. J Neurosci 18:6871-6881.
13. Bradaia A, Trouslard J. 2002. Fast synaptic transmission mediated by alpha-bungarotoxin- sensitive nicotinic acetylcholine receptors in lamina X neurones of neonatal rat spinal cord. J Physiol 544: 727-739.
14. 3H] nicotine binding in human postmortem brain. J Pharm Exp Ther 282: 7-13.
15. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, Marks MJ, Collins AC, Leonard S. 2000. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23: 351-364.
16. Buisson B, Bertrand D. 2002. Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci. 23:130-136.
17. Cohn T, Dunn E, Kameh H, Remington G. 2003. Cigarette Smoking and diabetes in schizophrenia: Evidence for an inverse correlation. Late-breaking data. Int Schiz Cong, Colorado Springs, April 2003.
18. Conti-Fine BM, Navaneetham D, Lei S, Maus ADJ. 2000. Neuronal nicotinic receptors in non-neuronal cells: new mediators of tobacco toxicity? Eur J Pharmacol 393:279-294.
19. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, Perry E. 1999. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungaro-toxin and nicotine binding in the thalamus. J Neurochem 73:1590-1597.
20. Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. 1999. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 21: 195-202.
21. Dani JA, Heinemann S. 1996. Molecular and cellular aspects of nicotine abuse. Neuron 16:905-908.
22. Drisdel RC, Green WN. 2000. Neuronal alpha-bungarotoxin receptors are alpha 7 subunit homomers. J Neurosci 20:133-139.
23. Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR. 1995. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Gen 57:651-660.
24. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. 1992. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41:31-37.
25. Foulds, J. 1999. The relationship between tobacco use and mental disorders. Curr Opin Psych 12:303-306.
26. Frazier CJ, Rollins YD, Breese CR, Leonard S, Freedman R, Dunwiddie TV. 1998. Acetylcholine activates an alpha-bungaro-toxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18:1187-1195.
27. Freedman R, Hall M, Adler LE, Leonard S. 1995. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psych 38:22-33.
28. Freedman R, Coon H, MylesWorsley M, OrrUrtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W. 1997. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci 94:587-592.
29. Freedman R, Adler LE, Leonard S. 1999. Alternative phenotypes for the complex genetics of schizophrenia. Biol Psych 45:551-558.
30. Fryer JD, Lukas RJ. 1999. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem 72: 1117-1124.
31. Gault J, Robinson M, Berger R, Drebing C, Logel J, Hopkins J, Moore T, Jacobs S, Meriwether J, Choi MJ, Kim EJ, Walton K, Buiting K, Davis A, Breese CR, Freedman R, Leonard S. 1998. Genomic organization and partial duplication of the human 7 neuronal nicotinic acetylcholine receptor gene. Genomics 52: 173-185.
32. Gault J, Hopkins J, Berger R, Drebing C, Logel J, Walton K, Short M, Vianzon R, Olincy A, Ross RG, Adler LE, Freedman R, Leonard S. 2003. Comparison of polymorphisms in the 7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects. Neuropsychopharmacology (in press).
33. George TP, Krystal JH. 2000. Comorbidity of psychiatric and substance abuse disorders. Curr Opin Psych 13:327-331.
34. George TP, Sernyak MJ, Ziedonis DM, Woods SW. 1995. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psych 56:344-346.
35. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR. 2002a. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psych 52:53-61.
36. George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, Kosten TR, Wexler BE. 2002b. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26:75-85.
37. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR. 2000c. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psych 157:1835-1842.
38. Glassman AH. 1993. Cigarette smoking: implications for psychiatric illness. Am J Psych 150:546-553.
39. Guan ZZ, Zhang X, Blennow K, Nordberg A. 1999. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 10: 1779-1782.
40. Guo JZ, Tredway TL, Chiappinelli VA. 1998. Glutamate and GABA release are enhanced by different subtypes of presynaptic nicotinic receptors in the lateral geniculate nucleus. J Neurosci 18:1963-1969.
41. Han SY, Sweeney JE, Bachman ES, Schweiger EJ, Forloni G, Coyle JT, David BM, Joullie MM. 1992. Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives: a potential application in Alzheimers disease. Eur J Med Chem 27:673-687.
42. Holm KJ, Spencer CM. 2000. Bupropion: a review of its use in the management of smoking cessation. Drugs 59:1007-1024.
43. Jones S, Sudweeks S, Yakel JL. 1999. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 22:555-561.
44. Ke L, Eisenhour CM, Bencherif M, Lukas RJ. 1998. Effects of chronic nicotine treatment on expression of diverse nicotinic acetylcholine receptor subtypes. I. Dose- and time-dependent effects of nicotine treatment. J Pharmacol Exp Ther 286:825-840.
45. Khiroug SS, Harkness PC, Lamb PW, Sudweeks SN, Khiroug L, Millar NS, Yakel JL. 2002. Rat nicotinic ACh receptor alpha 7 and beta 2 subunits co- assemble to form functional heteromeric nicotinic receptor channels. J Physiol Lond 540:425-434.
46. Lambe EK, Picciotto MR, Aghajanian GK. 2003. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 28:216-225.
47. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. 2000. Smoking and mental illness: a population-based prevalence study. JAMA 284:2606-2610.
48. Laviolette SR, van der Kooy D. 2003. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol Psych 8:50-59.
49. Lee MJ, Logel J, Gault J, Leonard S. 2001. Cloning and expression of variants of a partial duplication of the human α7 nicotinic receptor subunit. Soc Neurosci Abst 27: Program Number 144.10.
50. Leonard S, Bertrand D. 2001. Neuronal nicotinic receptors: from structure to function. Nic Tob Res 3:203-223.
51. Leonard S, Giordano L. 2002. Are differential behavioral responses to smoking and smoking cessation in schizophrenia related to nicotine receptor levels? Neuropsychopharmacology 27: 1082-1083.
52. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, Gault J, Lee MJ, Logel J, Olincy A, Ross RG, Stevens K, Sullivan B, Vianzon R, Vernich DE, Waldo M, Walton K, Freedman R. 2001. Smoking and mental illness. Pharmacol Biochem Behav 70:561-570.
53. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R. 2002. Association of promoter variants in the alpha 7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psych 59:1085-1096.
54. Levy RB, Aoki C. 2002. Alpha 7 nicotinic acetylcholine receptors occur at postsynaptic densities of AMPA receptor-positive and -negative excitatory synapses in rat sensory cortex. J Neurosci 22:5001-5015.
55. Lindstrom J. 1997. Nicotinic acetylcholine receptors in health and disease. Mol Neurobiol 15:193-222.
56. Lindstrom J, Schoepfer R, Whiting P. 1987. Molecular studies of the neuronal nicotinic acetylcholine receptor family. Mol Neurobiol 1:281-339.
57. Luntz-Leybman V, Bickford PC, Freedman R. 1992. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res 587:130-136.
58. Maelicke A, Albuquerque EX. 2000. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393:165-170.
59. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX. 2000. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 113:199-206.
60. Mahnir V, Lin B, Prokai-Tatrai K, Kem WR. 1998. Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition. Biopharm Drug Disp 19:147-151.
61. Marks MJ, Burch JB, Collins AC. 1983. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharm Exp Ther 226:817-825.
62. Marks MJ, Stitzel JA, Collins AC. 1986. A dose-response analysis of nicotine tolerance and receptor changes in two inbred mouse strains. J Pharm Exp Ther 239:358-364.
63. McEvoy JP, Allen TB. 2003. Substance abuse (including nicotine) in schizophrenic patients. Curr Opin Psych 16:199-205.
64. McEvoy J, Freudenreieh O, McGee M, Vanderzwaag C, Levin ED, Rose J. 1995. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psych 37:550-552.
65. McEvoy JP, Freudenreich O, Wilson WH. 1999. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psych 46:125-129.
66. McGehee DS, Role LW. 1995. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Ann Rev Physiol 57:521-546.
67. Meck WH, Williams CL. 1999. Choline supplementation during prenatal development reduces proactive interference in spatial memory. Dev Brain Res 118:51-59.
68. Meyer EM, Tay ET, Papke RL, Meyers C, Huang GL, de FC. 1997. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res 768:49-56.
69. Meyer EM, Tay ET, Zoltewicz JA, Meyers C, King MA, Papke RL, DeFiebre CM. 1998. Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties. J Pharmacol Exp Ther 284: 1026-1032.
70. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. 2002. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22:2718-2729.
71. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R. 1996. Gating of auditoty P50 in schizophrenics: Unique effects of clozapine. Biol Psych 40:181-188.
72. Olincy A, Ross RG, Young DA, Roath M, Freedman R. 1998. Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology 18:175-185.
73. Orr-Urtreger A, Broide RS, Kasten MR, Dani JA, Beaudet AL, Patrick J.W. 2000. Mice homozygous for the L250T mutation in the a7 nicotinic acetylcholine receptor show increased neuronal apoptosis and die within one day of birth. J Neurochem 74: 2154-2166.
74. Papke RL, Meyer E, Nutter T, Uteshev W. 2000. alpha 7 receptor-selective agonists and modes of alpha 7 receptor activation. Eur J Pharmacol 393:179-195.
75. Parada MA, De Parada MP, Hernandez L, Garcia F, Murzi E, Contrera, Q. 1998. Clozapine-induced acetylcholine release in the rat prefrontal cortex, nucleus accumbens and striatum does not develop tolerance. Prog Neuro-Psychopharmacol Biol Psych 22:1379-1397.
76. Pauly JR, Marks MJ, Robinson SF, van de Kamp JL, Collins AC. 1996. Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing alpha 4 or beta 2 mRNA levels. J Pharmacol Exp Ther 278:361-369.
77. Peng X, Gerzanich V, Anand R, Whiting PJ, Lindstrom J. 1994. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol 46:523-530.
78. Pereira EFR, Hilmas C, Santos MD, Alkondon M, Maelicke A, Albuquerque EX. 2002. Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 53:479-500.
79. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ. 1999. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharm Exp Ther 289:1545-1552.
80. Quick MW, Lester RAJ. 2002. Desensitization of neuronal nicotinic receptors. J Neurobiol 53:457-478.
81. Ross RG, Olincy A, Harris JG, Radant A, Hawkins M, Adler LE, Freedman R. 1999. Evidence for bilineal inheritance of physiological indicators of risk in childhood-onset schizophrenia. Am J Med Genet 88:188-199.
82. Rosse RB, Deutsch SI. 2002. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharm 25:272-275.
83. Sanderson EM, Drasdo AL, McCrea K, Wonnacott S. 1993. Upregulation of nicotinic receptors following continuous infusion of nicotine is brain-region-specific. Brain Res 617: 349-352.
84. Schilstrom B, Fagerquist MV, Zhang X, Hertel P, Panagis G, Nomikos GG, Svensson TH. 2000. Putative role of presynaptic alpha 7* nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse 38:375-383.
85. Sereno AB, Holzman PS, 1995. Antisaccades and smooth pursuit eye movements in schizophrenia. Biol Psych 37:394-401.
86. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J. 2000. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 148:33-40.
87. Shirazi-Southall S, Rodriguez DE, Nomikos GG. 2002. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26:583-594.
88. Simosky JK, Stevens KE, Kern WR, Freedman R. 2001. Intragastric DMXB-A, an alpha 7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol Psych 50:493-500.
89. Simosky JK, Stevens KE, Adler LE, Freedman R. 2003. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacoogy. 165:386-396.
90. Slemmer JE, Martin BR, Damaj MI. 2000. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327.
91. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks JM, Rose GM. 1996. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15:152-162.
92. Stevens KE, Kem WR, Mahnir VM, Freedman R. 1998. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 136: 320-327.
93. Summers KL, Kem WR, Giacobini E. 1997. Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex. Jpn J Pharmacol 74:139-146.
94. Tees RC. 1999. The influences of sex, rearing environment, and neonatal choline dietary supplementation on spatial and non-spatial learning and memory in adult rats. Dev Psychobiol 35: 328-342.
95. Uteshev VV, Meyer EM, Papke RL. 2003. Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors. J Neurophysiol 89:1797-1806.
96. ++. Neuron 8:353-362.
97. Watkins SS, Koob GF, Markou A. 2000. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nic Tob Res 2:19-37.
98. Weiner E, Ball MP, Summerfelt A, Gold J, Buchanan RW. 2001. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psych 158:635-637.
99. Weiser M, Reichenberg A, Grotto IYR, Knobler HY, Lubin G, Nahon D, Davidson M. 2003. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Schiz Res 60:55.
100. Wonnacott S. 1997. Presynaptic nicotinic ACh receptors. Trends Neurosci 20:92-98.
101. Yu CR, Role LW. 1998. Functional contribution of the alpha7 subunit to multiple subtypes of nicotinic receptors in embryonic chick sympathetic neurones. J Physiol 509:651-665.
102. Zhang Z-W, Vijayaraghavan S, Berg DK. 1994. Neuronal acetylcholine receptors that bind α-bungarotoxin with high affinity function as ligand-gated ion channels. Neuron 12:167-177.
103. Zhou FM, Liang Y, Dani JA. 2001. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 4:1224-1229.